Month: August 2022

Isofol provides update on the AGENT study

Pressmeddelande

GOTHENBURG, Sweden, August 31, 2022 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) today announced that, having received access to additional data, the company does not consider it justified to continue conducting the AGENT study. Review of study data will continue until the company can compile the final study report which is estimated to take place during the fourth quarter of 2022. At the same time, Isofol’s board of directors has decided to evaluate possible courses of action for the company’s future in order to maximize its value.

Isofol Announces Topline Results of Phase III AGENT Study – Did Not Meet Primary or Key Secondary Endpoints

Pressmeddelande

GOTHENBURG, Sweden, August 3, 2022 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), today announced topline results that neither the primary endpoint of Overall Response Rate (ORR) nor the key secondary endpoint in Progression Free Survival (PFS) achieved statistical significance in the multi-center, international Phase III AGENT Study of arfolitixorin in combination with 5-FU, oxaliplatin and bevacizumab in metastatic colorectal cancer (mCRC).

Scroll to Top